93 results
8-K
EX-99.1
AGIO
Agios Pharmaceuticals Inc
27 Oct 22
Agios and Sagard Healthcare Partners Announce $131.8 Million Purchase Agreement for TIBSOVO® Royalty
4:20pm
Exhibit 99.1
Agios and Sagard Healthcare Partners Announce $131.8 Million Purchase Agreement for TIBSOVO® Royalty
– Sagard Healthcare Partners … : AGIO), a leader in the field of cellular metabolism pioneering therapies for rare and genetically defined diseases, and Sagard Healthcare Partners
8-K
AGIO
Agios Pharmaceuticals Inc
8 Jan 24
Agios Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio
7:58am
at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024. The full text of the press release is furnished as Exhibit 99.1 … to this Current Report on Form 8-K and is incorporated herein by reference. The slides to be presented by the Company at the 42nd Annual J.P. Morgan Healthcare
8-K
tp57oa97
27 Oct 22
Agios and Sagard Healthcare Partners Announce $131.8 Million Purchase Agreement for TIBSOVO® Royalty
4:20pm
8-K
EX-99.1
ms1pf8
13 Jan 20
Agios Announces “Agios 2025” Strategic Vision and Highlights 2020 Milestones
6:43am
8-K
EX-99.1
46ibf6fj8k
8 Jan 24
Agios Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio
7:58am
DEFA14A
wwzadk ayriba0g
11 Jan 21
Additional proxy soliciting materials
7:17am
8-K
EX-99.1
3b8xdizshl kqk
3 Nov 22
Agios Reports Business Highlights and Third Quarter 2022 Financial Results
7:02am
DEFA14A
sbxgut
12 Jan 21
Additional proxy soliciting materials
5:15pm
8-K
EX-99.1
8wmze3ft
7 Jan 19
Agios Highlights Key 2019 Initiatives to Broaden Potential for Late-Stage Cancer and Rare Genetic Disease Programs to Build Long-Term Value
7:48am